[Show abstract][Hide abstract] ABSTRACT: Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody conjugated with the cytotoxic drug monomethylyauristatin E (MMAE), a potent microtubule inhibitor. In re-lapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma, BV achieved durable response with low and transitory toxicity. Accordingly, it was approved by FDA in 2011 for patients affected by these malignancies. In some case reports, BV obtained rapid response in CD30-expressing cutaneous T-cell lymphoma, as transformed mycosis fungoides and relapsed/refractory primary cutaneous ACL lymphoma. Currently, two phase 2 trials are ongoing to assess the potential use of brentuximab in patients af-fected by refractory/relapsed CD30+ T-cell lymphoproliferative disorders and in patients affected by mycosis fungoides/Sézary syndrome, respectively. Finally, one phase 3 trial is comparing brentuximab to methotrexate or bexarotene in CD30-expressing cutaneous T-cell lymphomas. Among the several new drugs tested in the last 5 years, BV showed the most promising and challenging results to be translated in the clinical practice.
[Show abstract][Hide abstract] ABSTRACT: Brentuximab vedotin (BV), a monomethyl auristatin E-conjugated anti-CD30 monoclonal antibody, has shown its efficacy in patients with Hodgkin and anaplastic large-cell lymphomas (ALCL). We report our experience with BV in 2 patients with transformed mycosis fungoides (MF) and transformed Sezary Syndrome (SS).This article is protected by copyright. All rights reserved.
No preview · Article · Aug 2014 · British Journal of Dermatology
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.